Yankun Liang
Guangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
SSRIs-induced liver injury adverse events: a data-based retrospective study and investigation of potential toxicological mechanisms.
Journal: Frontiers in pharmacology
Published: March 30, 2026
Age-stratified pharmacovigilance of azithromycin: a multimethod signal detection analysis in the FAERS database.
Journal: Journal of pharmaceutical policy and practice
Published: July 10, 2025
Congenital anomalies associated with the use of cardiovascular drugs during pregnancy: a large-scale data analysis from the FAERS database.
Journal: Expert opinion on drug safety
Published: December 13, 2024
Neurological drugs induced congenital anomalies: A pharmacovigilance analysis of neonatal reports in the FDA adverse event reporting system (FAERS).
Journal: Journal of affective disorders
Published: October 28, 2024
Adverse events associated with azithromycin and clarithromycin in adults aged ≥65: a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database.
Journal: Expert opinion on drug safety
Published: October 02, 2024
Age-stratified analysis of adverse event signals for clarithromycin: a disproportionality analysis using the FDA Adverse Event Reporting System.
Journal: Therapeutic advances in drug safety
Published: September 25, 2024
Risk of congenital anomalies associated with psychotropic medications: a review of neonatal reports in the FDA adverse event reporting System (FAERS).
Journal: Archives of women's mental health
Published: August 09, 2024
Association of incretin-based therapies with hepatobiliary disorders among patients with type 2 diabetes: a case series from the FDA adverse event reporting system.
Journal: Endocrine connections
Published: August 06, 2024
Adverse Events Associated With Dabrafenib, Trametinib, and Their Combination Therapy: A Disproportionality Analysis of the FDA Adverse Event Reporting System (FAERS) Database.
Journal: Pharmacoepidemiology and drug safety
Published: July 20, 2024
Gastrointestinal adverse events associated with Lenvatinib versus Lenvatinib plus Pembrolizumab: A pharmacovigilance study in FDA adverse event reporting system.
Journal: Scientific reports
Published: May 26, 2024
Last Updated: 09/26/2026